Are bisphosphonates the suitable anticancer drugs for the elderly?

Critical Reviews in Oncology/Hematology

Volumn 69, Issue 1, 2009, Pages 83-94

  Santini, Daniele ^a   Fratto, Maria Elisabetta ^a   Galluzzo, Sara ^a   Vincenzi, Bruno ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Bisphosphonates; Bone metastasis; Elderly; Survival

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GONADORELIN DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ELDERLY CARE; HIGH RISK PATIENT; HUMAN; LUNG CANCER; MULTIPLE MYELOMA; PROSTATE CANCER; QUALITY OF LIFE; REVIEW;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DIPHOSPHONATES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 56449113390     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.07.008     Document Type: Review

References (57)

1. Yancik R., and Ries L.A. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14 (2000) 17-23
2. Tralongo P., Repetto L., Di Mari A., et al. Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology 67 (2004) 112-116
3. Barkin R.L., Barkin S.J., and Barkin D.S. Perception, assessment, treatment, and management of pain in the elderly. Clin Geriatr Med 21 3 (2005) 465-490
4. Coleman R.E. Skeletal complications of malignancy. Cancer 80 8 Suppl. (1997) 1588-1594
5. Saad F., Lipton A., Cook R., Chen Y.M., Smith M., and Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110 8 (2007) 1860-1867
6. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev (2007) [Epub ahead of print]
7. Gridelli C. The use of bisphosphonates in elderly cancer patients. Oncologist 12 1 (2007) 62-71
8. Pillai G., Gieschke R., Goggin T., Barrett J., Worth E., and Steimer J.L. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. Int J Clin Pharmacol Ther 44 12 (2006) 655-667
9. Goldschmidt H., Lannert H., Bommer J., and Ho A.D. Multiple myeloma and renal failure. Nephrol Dial Transplant 15 (2000) 301-304
10. Patterson W.P., and Reams G.P. Renal toxicities of chemotherapy. Semin Oncol 19 (1992) 521-858
11. Tanvetyanon T., and Stiff P.J. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17 (2006) 897-907
12. Body J.J., Coleman R., Clezardin P., Ripamonti C., Rizzoli R., and Aapro M. International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 43 (2007) 852-858
13. Santini D., Fratto M.E., Vincenzi B., et al. Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther 6 12 (2006) 1333-1348
14. Clézardin P., Ebetino F.H., and Fournier P.G.J. Bisphosphonates and cancer induced bone disease: beyond their antiresorptive activity. Cancer Res 65 (2005) 4971-4974
15. Santini D., Vespasiani Gentilucci U., Vincenzi B., et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14 (2003) 1468-1476
16. Santini D., Galluzzo S., Vincenzi B., et al. New developments of aminobisphosphonates: the double face of Janus. Ann Oncol 18 Suppl. 6 (2007) vi164-vi167
17. Caraglia M., Santini D., Marra M., et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13 (2006) 7-26
18. Hillner B.E., Ingle J.N., Berenson J.R., et al. American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18 (2000) 1378-1391
19. Daubiné F., Céline Le Gall C., Gasser J., Green J., and Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. JNCI 99 4 (2007) 322-330
20. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
21. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
22. Rosen L.S., Gordon D., Tchekmedyian S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100 12 (2004) 2613-2621
23. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23 (2005) 3314-3321
24. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19 3 (2008) 420-432
25. Body J.J., Diel I.J., Bell R., et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111 (2004) 306-312
26. Tripathy D., Lichinitzer M., Lazarev A., et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 15 5 (2004) 743-750
27. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14 (2003) 1399-1405
28. Berenson J.R., Rosen L.S., Howell A., et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91 7 (2001) 1191-1200
29. Dimopoulos M., Berenson J., Shirina N., and Chen Y.M. Survival in patients with multiple myeloma receiving zoledronic acid: stratification by baseline bone alkaline phosphatase levels. Proc Am Soc Clin Oncol (2006) [Abstract no: 7505]
30. Costa L., Demers L.M., Gouveia-Oliveira A., et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20 (2002) 850-856
31. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 22 (2005) 4925-4935
32. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97 1 (2005) 59-69
33. Rosen L.S., Gordon D., Tchekmedyian S., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21 16 (2003) 3150-3157
34. Matczak E., Hirsh V., Lipton A., et al. Effects of zoledronic acid on survival in patients with lung cancer and high baseline N-telopeptide (NTX) levels: stratified by baseline bone alkaline phosphatase (BALP). Proc Am Soc Clin Oncol (2006) [Abstract no: 7228]
35. Cook R.J., Hirsh V., Major P.P., et al. Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD): survival in patients with high bone turnover. Proc Am Soc Clin Oncol (2008) [Abstract no: 20562]
36. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7 (2001) 377-387
37. Lipton A., Cook R., Major P., et al. Survival in breast cancer patients with bone metastases and reductions in markers of bone resorption during zoledronic acid treatment. Breast Cancer Res Treat (2006) [Abstract no: 508]
38. Lipton A., Cook R., Coleman R.E., et al. Normalization of bone markers and improved survival during zoledronic acid therapy. Proc Am Soc Clin Oncol (2007) [Abstract no: 9013]
39. Mystakidou K., Katsouda E., Parpa E., et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 22 (2005) 195-201
40. Saad F. Benefits of zoledronic acid in the treatment of prostate cancer: survival and antitumor effects. Proc Am Soc Clin Oncol (2007) [Abstract no: 283]
41. Lipton A., Zheng M., and Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98 (2003) 962-969
42. Brufsky A., Bosserman L., Caradonna R., et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. Breast Cancer Res Treat (2007) [Abstract no: 27]
43. Avilés A., Nambo M.J., Neri N., Castañeda C., Cleto S., and Huerta-Guzmán J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 24 2 (2007) 227-230
44. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339 (1998) 357-363
45. Powles T., McCroskey E., and Paterson A. Oral bisphosphonates as adjuvant therapy for operable breast cancer. Clin Cancer Res 12 (2006) 6301s-6304s
46. Saarto T., Vehmanen L., Blomqvist C., and Elomaa I. 10-year follow-up of the efficacy of clodronate on bone mineral density (BMD) in early stage breast cancer. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18 Suppl. (2006) [Abstract 676]
47. Jaschke A., Bastert G., Solomayer E.F., et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow-a longtime follow-up. J Clin Oncol 22 (2004) 529 [Meeting Abstracts]
48. Ha T.C., and Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 6 (2007) 1796-1801
49. Mason M.D., Sydes M.R., Glaholm J., et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 99 10 (2007) 765-776
50. Janni W., Hepp F., Rjosk D., et al. The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 92 (2001) 46-53
51. Rack B.K., Janni W., Schindlbeck C., et al. Effect of zoledronate on persisting isolated tumor cells (ITC) in the bone marrow (BM) of patients without recurrence of early breast cancer. Proc Am Soc Clin Oncol 23 (2004) 834 [Abstract 9515]
52. Lin A, Park J, Melisko M., et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Presented at SABCS 2007. [Abstract 510].
53. Aft R., Watson M., Ylagan L., et al. Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer. Proc Am Soc Clin Oncol (2008) [Abstract 1021]
54. Lin A.Y., Park J.W., Scott J., et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. Proc Am Soc Clin Oncol (2008) [Abstract 559]
55. Coleman R, Thorpe H, Cameron D, et al. Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy-first safety data from the AZURE trial (BIG01/04) [poster]. Presented at 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 14-17, 2006. [Abstract 2080].
56. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., et al. Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid-new results from ABCSG-12. Breast Cancer Res Treat (2007) [Abstract no: 26]
57. Gnant M., Mlineritsch B., Schippinger W., et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12. Proc Am Soc Clin Oncol (2008) [Abstract LBA4]